Effectiveness of abatacept for patients with Sjögren’s syndrome associated with rheumatoid arthritis. An open label, multicenter, one-year, prospective study: ROSE (Rheumatoid Arthritis with Orencia Trial toward Sjögren’s syndrome Endocrinopathy) trial

References

• Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61:554–8.
   PubMed Web of Science ®Google Scholar
• Tsuboi H, Asashima H, Takai C, Hagiwara S, Hagiya C, Yokosawa M, et al. Primary and secondary surveys on epidemiology of Sjogren's syndrome in Japan. Mod Rheumatol. 2014;24:464–70.
   PubMed Web of Science ®Google Scholar
• Wang D, Li Y, Liu Y, Shi G, et al. The use of biologic therapies in the treatment of rheumatoid arthritis. Curr Pharm Biotechnol. 2014;15:542–8.
   PubMed Web of Science ®Google Scholar
• Mok CC. Emerging biological therapies for systemic lupus erythematosus. Expert Opin Emerg Drugs. 2014;19:303–22.
   PubMed Web of Science ®Google Scholar
• Mozaffari S, Nikfar S, Abdolghaffari AH, Abdollahi M, et al. New biologic therapeutics for ulcerative colitis and Crohn's disease. Expert Opin Biol Ther. 2014;14:583–600.
   PubMed Web of Science ®Google Scholar
• Lynch M, Kirby B, Warren RB. Treating moderate to severe psoriasis—best use of biologics. Expert Rev Clin Immunol. 2014;10:269–79.
   PubMed Web of Science ®Google Scholar
• Vishwanath S, Relan M, Shen L, Ambrus JL Jr, et al. Update on the use of biologics in vasculitides. Curr Pharm Biotechnol. 2014;15:558–62.
   PubMed Web of Science ®Google Scholar
• Sada PR, Isenberg D, Ciurtin C. Biologic treatment in Sjögren's syndrome. Rheumatology (Oxford). 2015;54:219–30.
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Brito-Zerón P, Sisó-Almirall A, Bosch X, Tzioufas AG, et al. Topical and systemic medications for the treatment of primary Sjögren's syndrome. Nat Rev Rheumatol. 2012;8:399–411.
   PubMed Web of Science ®Google Scholar
• Dass S, Bowman SJ, Vital EM, Ikeda K, Pease CT, Hamburger J, et al. Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis. 2008;67:1541–4.
   PubMed Web of Science ®Google Scholar
• Meijer JM, Meiners PM, Vissink A, Spijkervet FK, Abdulahad W, Kamminga N, et al. Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010;62:960–8.
   PubMed Web of Science ®Google Scholar
• Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, Berthelot JM, Perdriger A, Puéchal X, et al. Treatment of primary Sjögren syndrome with rituximab: a randomized trial. Ann Intern Med. 2014;160:233–42.
   PubMed Web of Science ®Google Scholar
• Mariette X, Ravaud P, Steinfeld S, Baron G, Goetz J, Hachulla E, et al. Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS). Arthritis Rheum. 2004;50:1270–6.
   PubMed Web of Science ®Google Scholar
• Sankar V, Brennan MT, Kok MR, Leakan RA, Smith JA, Manny J, et al. Etanercept in Sjögren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum. 2004;50:2240–5.
   PubMed Web of Science ®Google Scholar
• Mariette X, Seror R, Quartuccio L, Baron G, Salvin S, Fabris M, et al. Efficacy and safety of belimumab in primary Sjögren's syndrome: results of the BELISS open-label phase II study. Ann Rheum Dis. 2015;74:526–31.
   PubMed Web of Science ®Google Scholar
• Singh N, Cohen PL. The T cell in Sjogren's syndrome: force majeure, not spectateur. J Autoimmun. 2012;39:229–33.
   PubMed Web of Science ®Google Scholar
• Sumida T, Tsuboi H, Iizuka M, Hirota T, Asashima H, Matsumoto I, et al. The role of M3 muscarinic acetylcholine receptor reactive T cells in Sjögren's syndrome: a critical review. J Autoimmun. 2014;51:44–50.
   PubMed Web of Science ®Google Scholar
• Adler S, Körner M, Förger F, Huscher D, Caversaccio MD, Villiger PM, et al. Evaluation of histological, serological and clinical changes in response to abatacept treatment of primary Sjögren's syndrome: a pilot study. Arthritis Care Res (Hoboken). 2013;65:1862–8.
   PubMed Web of Science ®Google Scholar
• Meiners PM, Vissink A, Kroese FG, Spijkervet FK, Smitt-Kamminga NS, Abdulahad WH, et al. Abatacept treatment reduces disease activity in early primary Sjogren's syndrome (open-label proof of concept ASAP study). Ann Rheum Dis. 2014;73:1393–6.
   PubMed Web of Science ®Google Scholar
• Tsuboi H, Matsumoto I, Hagiwara S, et al. Efficacy and safety of abatacept for patients with Sjögren's syndrome associated with rheumatoid arthritis: rheumatoid arthritis with orencia trial toward Sjögren's syndrome Endocrinopathy (ROSE) trial - an open-label, one-year, prospective study - Interim analysis of 32 patients for 24 weeks. Mod Rheumatol. 2015;25:187–93.
   PubMed Web of Science ®Google Scholar
• Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–24.
   PubMed Web of Science ®Google Scholar
• Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62:2569–81.
   PubMed Web of Science ®Google Scholar
• Fujibayashi T, Sugai S, Miyasaka N, Hayashi Y, Tsubota K, et al. Revised Japanese criteria for Sjögren’s syndrome (1999): availability and validity. Mod Rheumatol. 2004;14:425–34.
   PubMedGoogle Scholar
• Yokosawa M, Tsuboi H, Nasu K, Hagiya C, Hagiwara S, Hirota T, et al. Usefulness of MR imaging of the parotid glands in patients with secondary Sjögren's syndrome associated with rheumatoid arthritis. Mod Rheumatol. 2015;25:415–20.
   PubMed Web of Science ®Google Scholar
• Guyot P, Taylor P, Christensen R, Pericleous L, Poncet C, Lebmeier M, et al. Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis. Arthritis Res Ther. 2011;13:R204.
   Google Scholar
• He J, Ding Y, Feng M, Guon J, Sun X, Zhao J, et al. Characteristics of Sjögren's syndrome in rheumatoid arthritis. Rheumatology (Oxford). 2013;52:1084–9.
   PubMed Web of Science ®Google Scholar
• Matsudaira R, Tamura N, Sekiya F, Ogasawara M, Yamanaka K, Takasaki Y, et al. Anti-Ro/SSA antibodies are an independent factor associated with an insufficient response to tumor necrosis factor inhibitors in patients with rheumatoid arthritis. J Rheumatol. 2011;38:2346–54.
   PubMed Web of Science ®Google Scholar
• Scarsi M, Paolini L, Ricotta D, Pedrini A, Piantoni S, Caimi L, et al. Abatacept reduces levels of switched memory B cells, autoantibodies, and immunoglobulins in patients with rheumatoid arthritis. J Rheumatol. 2014;41:666–72.
   PubMed Web of Science ®Google Scholar